Biomedical subjects

Bozena Jaźwiec

Publications and source records attributed to Bozena Jaźwiec.

10 recordsLinked to original sources

PubMed2006

Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia.

Syndecan-1 (CD138) is a transmembrane heparin sulfate proteoglycan expressed on distinct stages of differentiation of B-lymphoid cells. Its prognostic value in B-cell chronic lymphocytic leukemia (B-CLL) has not been evaluated so far. The serum concentration of sCD138 and some angiogenesis-involved cytokines: vascular endothelial growth factor (VEGF), basis fibroblast growth factor (bFGF), and endostatin were studied in 52 previously untreated patients with B-CLL. We found that bFGF and sCD138 levels were significantly higher in B-CLL patients than in controls. In patients with sCD138 level or endostatin level below the median value the lymphocyte count was higher than in patients with serum level of those cytokines above the median value. In patients with progressive disease bFGF level was significantly higher and sCD138 level significantly lower than in patients with stable one. Moreover, high sCD138 level was associated with longer lymphocyte doubling-free survival, and, on the limit of statistical significance, a high endostatin level was associated with shorter progression-free survival. We conclude that serum sCD138 level is increased in early stage B-CLL patients and may have a positive prognostic value as to the dynamics of the disease.

Adult↗

PubMed2005

Changes in spectrin organisation in leukaemic and lymphoid cells upon chemotherapy.

The aim of the present study was to investigate changes in spectrin and protein kinase C theta; (PKC theta;) organisation in human lymphoid and leukaemic cells undergoing chemotherapeutically induced apoptosis. An analysis of spectrin arrangement in human peripheral lymphoid (non-Hodgkin lymphoma) and leukaemic (acute lymphoblastic leukaemia) cells before and after chemotherapy revealed radical differences in the distribution of this protein. By using immunofluorescent technique, in lymphocytes isolated before chemotherapy, we found spectrin evenly distributed in the cytoplasm and the plasma membrane, while after the therapy changes in spectrin organisation occurred. Moreover, in lymphocytes after chemotherapy, extraction with buffer containing non-ionic detergent (Triton X-100) revealed presence of an insoluble fraction of spectrin. In normal or malignant cells before chemotherapy spectrin was totally soluble, however it should be mentioned that in total cell extracts and supernatants (but not in pellets) apoptotic fragments of spectrin (in addition to intact alpha and beta chains) were also found. In malignant cells after chemotherapy changes in PKC theta; organisation, similar to this observed in the case of spectrin, were shown by the immunofluorescence technique. In contrast, no differences in the distribution of other isoforms of protein kinase C: betaI and betaII, before and after chemotherapy, were found. Apoptotic phosphatidyloserine (PS) externalisation, as well as cell shrinkage, membrane protrusions and blebbing were observed in lymphocytes after chemotherapy and treatment with cytostatics in vitro. The overall results may suggest that spectrin redistribution/aggregation is the phenomenon involved in programmed cell death (PCD) of normal and neoplastic lymphocytes and lymphoblasts, however molecular basis of this phenomenon should be further investigated.

Cells, Cultured↗

PubMed2005

[Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas].

Circulating endothelial cells and their precursors are suggested by some authors to be novel markers of angiogenesis. The aim of the study was to measure circulating endothelial cells (CEC), circulating endothelial precursors (CEP) and activated endothelial cells (aCEC) and serum concentrations of VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor), well-known proangiogenic factors in patients with haematological malignancies before and after chemotherapy. Measurements were carried out in 20 patients with acute leukemia, 21 with malignant lymphoma and with 20 with multiple myeloma. The number of CEC, CEP and aCEC was measured by means of 3-color flow cytometry and serum concentrations of VEGF and bFGF with ELISA. In patients with acute leukemias and lymphomas the number of CEC was significantly higher than in controls, and that high number correlated with worse prognosis in patients with lymphomas. The increased number of CEP at diagnosis in patients with acute leukemia and lymphoma correlated with worse prognosis. The number of aCEC was higher in leukemic and lymphoma groups. After chemotherapy the decrease in CEC and CEP numbers in patients with acute leukemia and lymphoma was observed. In patients with lymphoma the increased serum VEGF concentrations in comparison with healthy subjects were noted but in leukemic patients-lower concentrations of VEGF. The initial high concentrations of bFGF in all patients did not change after therapy and in patients with lymphoma correlated with worse prognosis. Results suggest that in patients with acute leukemias and lymphomas CEC and CEP may be the markers of malignant process correlating with clinical outcome. aCEC may have a similar role in both diseases. Also in patients with lymphoma VEGF may be a marker of disease activity. bFGF is connected with pathogenesis of acute leukemia, myeloma and lymphoma and in patients with lymphoma is a predictor of worse prognosis.

Adult↗

PubMed2005

31P MRS analysis of the phospholipid composition of normal human peripheral blood mononuclear cells (PBMC).

The aim of this investigation was to characterize the phospholipid composition of normal human blood mononuclear cells using 31P NMR spectroscopy. Mononuclear cells of peripheral blood were obtained from 10 volunteers. Phospholipid extracts were prepared from 60x10(6) cells according to modified Folch's method. An AMX 300 Bruker spectrometer 7.05 T was used. The 31P spectrum of phospholipid extracts from normal human PBMC consisted of 9 peaks, with one each for phosphatidylcholine (PC), plasmalogen of phosphatidylcholine (CPLAS), lysophosphatidylcholine (LPC), sphingomyelin (SM), phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS) and cardiolipin (CL), and another one due to the external reference substance, methylenediphosphonic acid (MDPA). The concentrations of these phospholipids (PL), based on the integral intensities, were as follows: 0.398 +/- 0.078 mmole/l for PC; 0.033 +/- 0.019 mmole/l for CPLAS; 0.155 +/- 0.043 mmole/l for SM; 0.266 +/- 0.104 mmole/l for PI+PE; 0.101 +/- 0.040 mmole/l for PS, and 0.026 +/- 0.033 mmole/l for CL. The results of this study confirmed that 31P MRS is a convenient tool for measuring the phospholipid concentrations of biological samples.

Adult↗

PubMed2004

[Plasma concentration of the shed form of L-selectin (sL-selectin) in patients with acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL) and its relation to the clinical course].

L-selectin plays a critical role in the initiation of normal leukocyte attachment to activated endothelium. It is expressed on most normal leukocytes and is also detectable on blast cells in ALL and AML. The shed form of L-selectin (sL-selectin) is found in plasma. High plasma sL-selectin levels were detectable in patients with AML and correlated with disease activity and poor prognosis. Little information is available on the clinical and prognostic significance of sL-selectin in ALL. The study was undertaken to determine sL-selectin levels during clinical course of patients with ALL and AML and to assess its role as a disease activity and prognostic factor. Heparinized plasma was obtained from 83 patients with newly diagnosed acute leukemia, including 30 with ALL, 50 with AML, 3 with biphenotypic leukemia and 19 healthy people. For some patients additional samples were taken in complete remission (CR) and relapse. sL-selectin was assayed using an ELISA method. The mean plasma sL-selectin concentration in all patients with acute leukemia was significantly higher than and in normals. Concentration of s-selectin L in patients with CR was significantly lower than at presentation and in the range of normals. sL-selectin plasma concentration in relapse was comparable to that from diagnosis. There was no significant difference in sL-selectin concentration between patients who entered CR after induction treatment and without CR. Patients with extramedullary disease had higher sL-selectin than patients without that manifestation. Monitoring of the sL-selectin concentration maybe useful for evaluating leukemia activity in both ALL and AML patients.

Adult↗

PubMed2003

Cystocyte and lymphocyte derived fusomes/spectrosomes: analogies and differences: a mini-review.

Structures analogous to Drosophila spectrosomes were found in mammalian lymphocytes. Repasky and colleagues discovered an intracellular spectrin-rich structure in lymphoid cells, which had far-reaching parallels with the fusome/spectrosome of D. melanogaster germ cells. This fact implies that spectrosomes may be characteristic not only of insect germ cells, but also that an analogous structure may play an important role in other cell types. The term "spectrosome" was first used by Lin and Spradling in 1995 to describe a large sphere of fusomal material in D. melanogaster germline stem cells and their differentiated daughter cells - cytoblasts. In the D. melanogaster ovary, membrane skeletal proteins such as ankyrin, alpha/beta spectrin as well as adducin-like Hts protein(s) were found in this specific organelle - spectrosome/fusome. These orgalelles are involved in the creation of mitotic spindles and D. melanogaster cyst formation and oocyte differentiation, but the role of analogous spectrin-based aggregates found in nucleated cells still remains unclear.

Animals↗

PubMed2003

[Cytogenetic changes and their prognostic significance in elderly acute myeloid leukemia].

Cytogenetic analyses were performed in 72 acute myeloid leukemia (AML) patients > or = 60 years old. Karyotype was normal in 35 (48.6%) patients (group III). 3 patients (4.2%) had favourable karyotype with t(15;17) as an isolated aberration (group IV). 21 patients (29.2%) had adverse karyotypes (group I) and 13 (18%) had intermediate karyotypes (group II). Adverse karyotypes were simple (< 3 aberrations), with add 3q, 5q-, 7q-, in 5 persons, and complex (> or = 3 aberrations) in 16. Karyotypes of 14 patients from the latter group contained > or = 5 aberrations. Laboratory and clinical data were comparable between groups with > or = 3 and with > or = 5 changes. In more than 2/3 complex karyotypes chromosome 5 and 7 aberrations also were found. AML clinical course of group II patients was more similar to that of group I than of groups III and IV. A frequency of complete remissions differed statistically between group I and the others and a frequency of complete and partial remissions together--between I + II and III + IV groups. Overall survival time differed statistically between all groups. There were significantly more patients with secondary AML in groups I and II than in group III. Analysis according to FAB did not show prognostic significance of this classification. Authors conclude that cytogenetics have a fundamental prognostic importance in AML of the elderly and should be taken into account in establishing therapeutic strategies.

Aged↗

PubMed2002

[Expression of p16INK4a, p15INK4b, p21WAF1/Clip1 cell cycle inhibitors on blastic cells in patients with acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL) ].

Cyclin-dependent kinases (cdk) play the important role in neoplastic transformation. Their activity depends on interaction with proteins called inhibitors. There are two groups of inhibitors: INK4 (p16INK4a, p15INK4b, p18INK4c, p19INK4d) and proteins p21WAF1/Clip1, p27Kip1, p57Kip2. Alteration of inhibitors expression was assessed in acute lymphoblastic leukemia (ALL) and in acute myeloblastic leukemia (AML), but the results are not clear. The aim of our study was to estimate p16INK4a, p15INK-4b, p21WAF1/Clip1 expression in blast cells in patients with AML and ALL by cytochemistry method and to compare with the result of treatment. Forty-two patients were included in the study, 23 with AML and 19 with ALL. Expression of inhibitors was considered as positive when detected in > 5% of blast cells. Complete remission (CR) rate in patients with positive expression p16INK4a and p15INK4b was statistically significantly higher than in patients with negative expression: for p16INK4a chi 2 = 7.78, p < 0.01, for p15INK4b, chi 2 with Yates' modification = 3.94, p < 0.05. There was no difference in CR rate in patients with positive and negative p21WAF1/Clip1 expression. Moreover the patients with simultaneous expression of three inhibitors reached CR more often than the others: chi 2 = 7.43, p = 0.01 for AML and chi 2 = 6.74, p < 0.01 for ALL. Our study indicates that estimation of p16INK4a, p15INK4b, p21WAF1/Clip1 expression in blast cells can be used as prognostic factor in acute leukemia.

Adult↗

PubMed2002

[Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemia].

Apoptosis mediated by the interaction of cytotoxic T lymphocyte with blast cell via Fas receptor/Fas ligand (FasL) pathway is a one of the mechanisms of immunological leukemia surveillance. There is few data on possible blocking of Fas receptor by soluble form of Fas (sFasL) present in serum and the role of blast cells as the source of this ligand. Forty-eight patients with de novo diagnosis of acute leukemia, 32 with myeloblastic (AML) and 16 with acute lymphoblastic leukemia (ALL) were studied. Fas expression on bone marrow leukemic blasts was determined by flow cytomertic immunofluorescent analysis and serum concentration of sFasL assessed at presentation, in remission and in relapse. Blasts of all patients expressed Fas at variable degree (0.8 to 100%). Fas expression was significantly higher on myelo--than on lymphoblasts. There was no relation between degree of Fas expression at diagnosis and remission rate. Concentration of sFasL in acute leukemia patients at diagnosis was significantly higher than in healthy control group, decreased to normal values in remission and rose again in relapse. There was a negative correlation between Fas expression on blasts and sFasL concentration at the time of diagnosis. Results obtained suggest that blast cells could be the source of soluble FasL in acute leukemia patients and that sFasL serum concentration could be used for monitoring of disease activity.

Adult↗

PubMedDate not supplied

Mitoxantrone changes spectrin-aminophospholipid interactions.

Understanding drug-membrane and drug-membrane protein interactions would be a crucial step towards understanding the action and biological properties of anthracyclines, as the cell membrane with its integral and peripheral proteins is the first barrier encountered by these drugs. In this paper, we briefly describe mitoxantrone-monolayer and mitoxantrone-bilayer interactions, focusing on the effect of mitoxantrone on the interactions between erythroid or nonerythroid spectrin with phosphatidylethanolamine-enriched mono- and bilayers. We found that mitoxantrone markedly modifies the interaction of erythroid and nonerythroid spectrins with phosphatidylethanolamine/phosphatidylcholine (PE/PC) monolayers. The change in delta pi induced by spectrins is several-fold larger in the presence of 72 nM mitoxantrone than in its absence: spectrin/mitoxantrone complexes induced a strong compression of the monolayer. Spin-labelling experiments showed that spectrin/mitoxantrone complexes caused significant changes in the order parameter measured using a 5'-doxyl stearate probe in the bilayer, but they practically did not affect the mobility of 16'-doxyl stearate. These results indicate close-to-surface interactions/penetrations without significant effect on the mid-region of the hydrophobic core of the bilayer. The obtained apparent equilibrium dissociation constants indicated relatively similar mitoxantrone-phospholipid and mitoxantrone-spectrin (erythroid and nonerythroid) binding affinities. These results might in part, explain the effect of mitoxantrone on spectrin distribution in the living cells.

Animals↗